[{"orgOrder":0,"company":"Prime Medicine","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Prime Medicine","amount2":0.17999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Prime Medicine \/ J.P. Morgan","highestDevelopmentStatusID":"1","companyTruncated":"Prime Medicine \/ J.P. Morgan"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Undisclosed","graph3":"Prime Medicine","amount2":0.17999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Technology","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Prime Medicine \/ J.P. Morgan","highestDevelopmentStatusID":"1","companyTruncated":"Prime Medicine \/ J.P. Morgan"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"Cimeio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"CD117-shielded Cell","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Prime Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Prime Medicine \/ Cimeio Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Prime Medicine \/ Cimeio Therapeutics"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"MaxCyte","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Genetic Therapy","moa":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Prime Medicine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Prime Medicine \/ Prime Medicine","highestDevelopmentStatusID":"3","companyTruncated":"Prime Medicine \/ Prime Medicine"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Prime Medicine","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"","sponsorNew":"Prime Medicine \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Prime Medicine \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"PM359","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Prime Medicine","amount2":0.13,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.16,"dosageForm":"","sponsorNew":"Prime Medicine \/ J.P. Morgan","highestDevelopmentStatusID":"5","companyTruncated":"Prime Medicine \/ J.P. Morgan"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"PM359","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Prime Medicine","amount2":0.16,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.16,"dosageForm":"","sponsorNew":"Prime Medicine \/ J.P. Morgan","highestDevelopmentStatusID":"5","companyTruncated":"Prime Medicine \/ J.P. Morgan"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"PM359","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Prime Medicine","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Prime Medicine \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Prime Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"T-Cell Therapy","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Prime Medicine","amount2":3.6099999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Prime Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Prime Medicine \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"T-Cell-based Therapy","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Prime Medicine","amount2":3.6099999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Prime Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"12","companyTruncated":"Prime Medicine \/ Bristol Myers Squibb"}]

Find Clinical Drug Pipeline Developments & Deals by Prime Medicine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The collaboration combines Prime Medicine’s precise, multiplex gene editing capabilities with BMS’s broad expertise in development and commercialization of novel ex vivo T-cell therapies.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          September 30, 2024

                          Lead Product(s) : T-Cell Therapy

                          Therapeutic Area : Hematology

                          Highest Development Status : Preclinical

                          Sponsor : Bristol Myers Squibb

                          Deal Size : $3,610.0 million

                          Deal Type : Collaboration

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Prime Medicine will design optimized Prime Editor reagents for a select number of targets, including reagents that use its Prime Assisted Site-Specific Integrase Gene Editing (PASSIGE™) technology.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : $110.0 million

                          September 30, 2024

                          Lead Product(s) : T-Cell-based Therapy

                          Therapeutic Area : Hematology

                          Highest Development Status : Preclinical

                          Sponsor : Bristol Myers Squibb

                          Deal Size : $3,610.0 million

                          Deal Type : Collaboration

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : PM359 is Prime Medicine’s candidate for chronic granulomatous disease (CGD), targeting the p47phox variant in this serious childhood condition.

                          Brand Name : PM359

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          April 29, 2024

                          Lead Product(s) : PM359

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Proceeds will fund PM359 development, utilizing prime editing technology on autologous hematopoietic stem cells as a potential treatment for chronic granulomatous disease.

                          Brand Name : PM359

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          February 20, 2024

                          Lead Product(s) : PM359

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : IND Enabling

                          Sponsor : J.P. Morgan

                          Deal Size : $161.0 million

                          Deal Type : Public Offering

                          blank

                          05

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Proceeds will fund PM359 development, using prime editing to modify autologous hematopoietic stem cells as a potential treatment for chronic granulomatous disease.

                          Brand Name : PM359

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          February 14, 2024

                          Lead Product(s) : PM359

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : IND Enabling

                          Sponsor : J.P. Morgan

                          Deal Size : $125.0 million

                          Deal Type : Public Offering

                          blank

                          06

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The net proceeds will be used to support the development of curative therapies by using Prime Editing to correct CFTR mutations at the natural genetic locus, for the treatment of Cystic Fibrosis (CF).

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          January 25, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : Cystic Fibrosis Foundation

                          Deal Size : $15.0 million

                          Deal Type : Funding

                          blank

                          07

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Under the agreement, Prime Medicine obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform, to develop a new class of differentiated, one-time, potentially curative genetic therapi...

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          August 01, 2023

                          Lead Product(s) : Genetic Therapy

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Discovery Platform

                          Recipient : MaxCyte

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          08

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Under the collaboration, Prime Medicine will receive an exclusive option to license Cimeio’s cell shielding technology for CD117-shielded HSC transplant, as well as in vivo editing of CD117-shielded HSCs, for genetic diseases.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          June 22, 2023

                          Lead Product(s) : CD117-shielded Cell

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Cimeio Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          09

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Company expects to use the net proceeds from the offering, for general corporate purposes and working capital, including the development of its drug product candidates.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          October 24, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Undisclosed

                          Sponsor : J.P. Morgan

                          Deal Size : $175.0 million

                          Deal Type : Public Offering

                          blank

                          10

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Company expects to use the net proceeds from the offering, for general corporate purposes and working capital, including the development of its drug product candidates.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          October 19, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Undisclosed

                          Sponsor : J.P. Morgan

                          Deal Size : $175.0 million

                          Deal Type : Public Offering

                          blank